2016 AIRTRIP TRIAL Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and dependance M Multicenter, double-blind, placebo-controlled, open-label, medication withdrawal study Objective: To determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis 21 Inclusion criteria: Patients of age 2-70 years who had recurrent idiopathic pericarditis (with > 3 previous recurrences) patients Anakinra (N=11) VS Placebo (N=10) PRIMARY OUTCOME 18 Recurrent pericarditis rate % Difference -1.95%; 95% CI -3.3 to -0.6%; P = 0.001 90 NA Flare-free survival, median (days) P<0.001 72 Conclusion: In patients with colchicine-resistant, steroid-dependent recurrent pericarditis, the IL-1B antagonist anakinra was associated with a dramatic reduction in the pericarditis recurrence rate of 18% compared to 90% in the placebo group at 14 months. Brucato A, et al; JAMA. 2016;316(18):1906-1912